Lactococcus lactis as a cell factory for delivery of therapeutic proteins
- PMID: 20156189
- DOI: 10.2174/156652310790945557
Lactococcus lactis as a cell factory for delivery of therapeutic proteins
Abstract
The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which recombinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.
Similar articles
-
Heterologous protein production and delivery systems for Lactococcus lactis.Genet Mol Res. 2003 Mar 31;2(1):102-11. Genet Mol Res. 2003. PMID: 12917806 Review.
-
Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.Int J Mol Sci. 2021 Jan 30;22(3):1379. doi: 10.3390/ijms22031379. Int J Mol Sci. 2021. PMID: 33573129 Free PMC article. Review.
-
A review on Lactococcus lactis: from food to factory.Microb Cell Fact. 2017 Apr 4;16(1):55. doi: 10.1186/s12934-017-0669-x. Microb Cell Fact. 2017. PMID: 28376880 Free PMC article. Review.
-
Construction of two Lactococcus lactis expression vectors combining the Gateway and the NIsin Controlled Expression systems.Plasmid. 2011 Sep;66(3):129-35. doi: 10.1016/j.plasmid.2011.07.001. Epub 2011 Jul 23. Plasmid. 2011. PMID: 21807023
-
Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract.Int J Food Microbiol. 2010 Nov 15;144(1):29-34. doi: 10.1016/j.ijfoodmicro.2010.08.017. Epub 2010 Aug 27. Int J Food Microbiol. 2010. PMID: 20851488
Cited by
-
Engineering integrative vectors based on phage site-specific recombination mechanism for Lactococcus lactis.BMC Biotechnol. 2019 Nov 27;19(1):82. doi: 10.1186/s12896-019-0575-x. BMC Biotechnol. 2019. PMID: 31775775 Free PMC article.
-
Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines (Basel). 2021 Dec 18;9(12):1497. doi: 10.3390/vaccines9121497. Vaccines (Basel). 2021. PMID: 34960243 Free PMC article. Review.
-
Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.Clin Vaccine Immunol. 2012 Jan;19(1):37-44. doi: 10.1128/CVI.05505-11. Epub 2011 Nov 9. Clin Vaccine Immunol. 2012. PMID: 22072720 Free PMC article.
-
PilVax - a novel peptide delivery platform for the development of mucosal vaccines.Sci Rep. 2018 Feb 7;8(1):2555. doi: 10.1038/s41598-018-20863-7. Sci Rep. 2018. PMID: 29416095 Free PMC article.
-
Codon Optimization is Required to Express Fluorogenic Reporter Proteins in Lactococcus lactis.Mol Biotechnol. 2024 Sep 23. doi: 10.1007/s12033-024-01285-5. Online ahead of print. Mol Biotechnol. 2024. PMID: 39312082
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources